Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib

Open access

Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib

The aim of the present study was to investigate the potential of nanoemulsion formulations for transdermal delivery of celecoxib (CXB). The in vitro skin permeation profile of optimized formulations was compared with CXB gel and nanoemulsion gel. Significant increase in the steady state flux (Jss), permeability coefficient (Kp) and enhancement ratio (Er) was observed in nanoemulsion formulations T1 and T2 (p < 0.05). The highest value of these permeability parameters was obtained in formulation T2, which consisted of 2% (m/m) of CXB, 10% (m/m) of oil phase (Sefsol 218 and Triacetin), 50% (m/m) of surfactant mixture (Tween-80 and Transcutol-P) and 40% (m/m) water. The anti-inflammatory effects of formulation T2 showed a significant increase (p < 0.05) in inhibition after 24 h compared to CXB gel and nanoemulsion gel on carrageenan-induced paw edema in rats. These results suggested that nanoemulsions are potential vehicles for improved transdermal delivery of CXB.

Dizajn, razvoj i vrednovanje novih nanoemulzija za transdermalnu primjenu celekoksiba

U radu su opisana ispitivanja nanoemulzija za transdermalnu primjenu celekoksiba (CXB). Profil permeacije kroz kožu ispitivan je in vitro i uspoređivan sa CXB gelom i nanoemulzijskim gelom. U formulacijama T1 i T2 postignuto je značajno povećanje ustaljenog fluksa (Jss), koeficijenta permeabilnosti (Kp) i povećanje omjera (Er) (p < 0.05). Najveće vrijednosti parametara permeabilnosti dobivene su u formulaciji T2 koja je sadržala 2% m/m CXB, 10% m/m uljne faze (Sefsol 218 i Triacetin), 50% m/m površinski-aktivnih tvari (Tween-80 i Transcutol-P) i 40% m/m vode. Protuupalno djelovanje formulacije T2 na edem šape štakora uzrokovan karageninom značajno je povećano (p < 0.05) poslije 24 h u usporedbi sa CXB gelom i nanoemulzijskim gelom. Rezultati ukazuju na poboljšanu isporuku celekoksiba putem nanoemulzija.

References
  • E. Escibano, A. C. Calpena, J. Queralt, R. Obach and J. Domenech, Assessment of diclofenac permeation with different formulations: anti-inflammatory study of a selected formula, Eur. J. Pharm. Sci.19 (2003) 203--210; DOI: 10.1016/S0928-0987(03)00103-9.

  • Gaurel, A. M. Martel and J. Castaner, Celecoxib, anti-inflammatory, cyclo-oxygenase-2 inhibitor, Drug Future22 (1997) 711--714.

  • K. A. Walters, Penetration Enhancers and their Use in Transdermal Therapeutic Systems, in Transdermal Drug Delivery: Developmental Issues and Research Initiatives (Eds. J. Hadgraft and R. H. Guy), Marcel Dekker, New York 1989, pp. 197--246.

  • D. W. Osborne, A. J. Ward and K. J. Neil, Microemulsions as topical delivery vehicles: in-vitro transdermal studies of a model hydrophilic drug, J. Pharm. Phamacol.43 (1991) 450--454.

  • M. Trotta, F. Pattarino and M. R. Gasco, Influence of counter ions on the skin permeation of methotrexate from water-oil microemulsions, Pharm. Acta. Helv.71 (1996) 135--140; DOI: 10.1016/0031-6865(96)00003-9.

  • S. Shafiq, S. Faiyaz, T. Sushma, J. A. Farhan, R. K. Khar and M. Ali, Design and development of ramipril nanoemulsion formulation: In vitro and in vivo assessment, J. Biomed. Nanotechnol.3 (2007) 28--44; DOI: 10.1166/jbn.2007.008.

  • S. Shafiq, S. Faiyaz, T. Sushma, J. A. Farhan, R. K. Khar and M. Ali, Development and bioavailability assessment of ramipril nanoemulsion formulation, Eur. J. Pharm. Biopharm.66 (2007) 227--243; DOI: org/10.1016/j.ejpb.2006.10.014.

  • M. B. Delgado-Charro, G. Iglesias-Vilas, J. Blanco-Mendez, M. J. Lopez-Quintela, M. A. Marty and J. P. Guy, Delivery of a hydrophilic solute through the skin from novel microemulsion systems, Eur. J. Pharm. Biopharm.43 (1997) 37--42; DOI: 10.1016/S0939-6411(96)00016-1.

  • M. Kreilgaard, E. J. Pedersen and J. W. Jaroszewski, NMR characterization and transdermal drug delivery potentials of microemulsion systems, J. Control. Rel.69 (2000) 421--433; DOI: 10.1016/S0168-3659(00)00325-4.

  • P. J. Lee, R. Langer and V. P. Shastri, Novel microemulsion enhancer formulation for simultaneous transdermal delivery of hydrophilic and hydrophobic drugs, Pharm. Res.20 (2003) 264--269; DOI: 10.1023/A:1022283423116.

  • M. Kreilgaard, Dermal pharmacokinetics of microemulsion formulations determined by in-vitro microdialysis, Pharm. Res.18 (2001) 367--373; DOI: 10.1023/A:1011067300397.

  • M. Kreilgaard, M. J. B. Kemme, J. Burggraaf, R. C. Schoemaker and A. F. Cohen, Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics, Pharm. Res.18 (2001) 593--599; DOI: 10.1023/A:1011068907416.

  • M. R. Gasco, M. Gallarate and F. Pattarino, In-vitro permeation of zelaic acid from viscosized microemulsions, Int. J. Pharm.69 (1991) 193--196; DOI: 10.1016/0378-5173(91)90361-Q.

  • K. Kriwet and C. C. Muller-Goymann, Diclofenac release from phospholipids drug systems and permeation through excised human stratum corneum, Int. J. Pharm.125 (1995) 231--242; DOI: 10.1016/0378-5173(95)00130-B.

  • S. Baboota, F. Shakeel, A. Ahuja, J. Ali, S. Shafiq and S. Ahmed, Development and validation of stability indicating HPLC method for analysis of Celecoxib in bulk drug and microemulsion formulations, Acta Chromat. (in press).

  • N. J. Van Abbe, P. Nicholas and E. Boon, Exaggerated exposure in topical irritancy and sensitization testing, J. Soc. Cosmet. Chem.26 (1975) 173--187.

  • C. A. Winter, Anti-inflammatory testing methods: Comparative evaluation of indomethacin and other agents, NSAID, 82 (1965) 190--202.

  • M. N. Gosh, Fundamentals of Experimental Pharmacology, 3rd ed., Hilton and Co., Kolkata 2005, p. 192.

  • D. Q. M. Craig, S. A. Barker, D. Banning and S. W. Booth, An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy, Int. J. Pharm.114 (1995) 103--110; DOI: 10.1016/0378-5173(94)00222-Q.

  • K. Kawakami, T. Yoshikawa, Y. Moroto, E. Kanaoka, K. Takahashi, Y. Nishihara and K. Masuda, Microemulsion formulation for enhanced absorption of poorly soluble drugs I. Prescription design, J. Control. Rel.81 (2002) 65--74; DOI: 10.1016/S0168-3659(02)00049-4.

  • M. J. Lawrence and G. D. Rees, Microemulsion-based media as novel drug delivery systems, Adv. Drug Deliv. Rev.45 (2000) 89--121; DOI: 10.1016/S0169-409X(00)00103-4.

  • W. Warisnoicharoen, A. B. Lansley and M. J. Lawrence, Light scattering investigations on dilute non-ionic oil-in-water microemulsions, AAPS PharmSci.2 (2000) article 12; DOI: 10.1208/ps020212.

  • L. Ping, A. Ghosh, R. F. Wagner, S. Krill, Y. M. Joshi and A. T. M. Serajuddin, Effect of combined use of nonionic surfactant on formation of oil-in-water microemulsions, Int. J. Pharm.288 (2005) 27--34; DOI: 10.1016/jijpharm.2004.08.024.

  • K. Shinoda and H. Kunieda, Phase Properties of Emulsions: PIT and HLB, in Encyclopedia of Emulsion Technolog (Eds. K. Shinoda and H. H. Kunieda), Marcel Dekker, New York 1983, pp. 337--367.

  • N. J. Kale and A. V. Allen, Studies on microemulsions using Brij-96 as surfactant and glycerin, ethylene glycol and propylene glycol as cosurfactants, Int. J. Pharm.57 (1998) 87--93; DOI: 10. 1016/0378-5173(89)90296-2.

  • D. Thacrodi and R. K. Panduranga, Transdermal absorption of nifedipine from microemulsions of lipophilic skin penetration enhancers, Int. J. Pharm.111 (1994) 235--240; DOI: 10.1016/0378--5173(94)90346-8.

Acta Pharmaceutica

The Journal of Croatian Pharmaceutical Society

Journal Information


IMPACT FACTOR 2016: 1.288
5-year IMPACT FACTOR: 1.600

CiteScore 2016: 1.55

SCImago Journal Rank (SJR) 2016: 0.353
Source Normalized Impact per Paper (SNIP) 2016: 0.854

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 37 37 37
PDF Downloads 6 6 6